Results 11 to 20 of about 952 (211)
Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid [PDF]
Frontiers in Immunology, 2019 Bullous pemphigoid (BP) is an organ-specific autoantibody-mediated blistering skin disease that mainly affects the elderly. Typical clinical features include the widespread blisters, often preceded by and/or associated with itchy urticarial or eczema ...
Kaisa Tasanen +2 more
doaj +4 more sources
The role of dipeptidyl peptidase-4 inhibitors
BMJ, 2012 Will be clearer once ongoing trials are complete Type 2 diabetes is a progressive disease and greater treatment intensity is needed over time to control increasingly abnormal glucose concentrations.1 In the linked article (doi:10.1136/bmj.e1369), Karagiannis and colleagues present a systematic review and meta-analysis of the risks and benefits ...
Lasserson, D, Mant, J
openaire +4 more sources
The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors [PDF]
BioMed Research International, 2014 A cell surface serine protease, dipeptidyl peptidase 4 (DPP-4), cleaves dipeptide from peptides containing proline or alanine in the N-terminal penultimate position. Two important incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), enhance meal-stimulated insulin secretion from pancreaticβ-cells, but ...
Kim, Na-Hyung, Yu, Taeyang, Lee, Dae Ho
openaire +2 more sources
Clinical Case Reports, 2020 We experienced two cases of dipeptidyl peptidase‐4 (DPP‐4) inhibitor‐associated bullous pemphigoid (BP) showing an unfavorable course despite its discontinuation.
Yasutake Shinohara +8 more
doaj +1 more source
Journal of Diabetes Investigation, 2023 Aims/Introduction This study aimed to understand the characteristics of type 2 diabetes subjects enrolled in randomized controlled trials (RCTs) and non‐RCTs according to therapeutic regimens through systematic literature review.
Takashi Kadowaki +2 more
doaj +1 more source
Frontiers in Immunology, 2022 Bullous pemphigoid (BP) is a rare autoimmune blistering disease, and the prevalence of type 2 diabetes mellitus (T2DM) is relatively high in subjects with BP. It is known that dipeptidyl peptidase-4 inhibitor (DPP-4i), one kind of antidiabetic drugs, can
Yuichiro Iwamoto +8 more
doaj +1 more source
Journal of Pharmacological Sciences, 2004 The effects of orally administered dipeptidyl peptidase IV (DPP-IV) inhibitor on the glucose-lowering effect of glibenclamide are still unknown. We evaluated the effects of combination treatment with a long-lasting DPP-IV inhibitor, K579 ((S)-1-[4-methyl-
Kotaro Takasaki +4 more
doaj +1 more source
The pleiotropic cardiovascular effects of dipeptidyl peptidase‐4 inhibitors [PDF]
British Journal of Clinical Pharmacology, 2018 Patients with Type 2 diabetes have an excess risk for cardiovascular disease. One of the several approaches, included in the guidelines for the management of Type 2 diabetes, is based on dipeptidyl peptidase 4 (DPP‐4; also termed CD26) inhibitors, also called gliptins.
Avogaro, Angelo, Fadini, Gian Paolo
openaire +3 more sources
Angewandte Chemie, EarlyView.Peptide‐to‐Small Molecule Paradigm: Peptidomimetics have evolved from simple mimicry toward drug‐like scaffolds supported by increasing clinical successes. This Perspective highlights the geometric design principles—linear repetition, convergent fusion, and cyclization—defining the next‐generation peptidomimetic architectures capable of targeting ...
Jesang Lee +5 more
wiley +2 more sources
An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin
Journal of Medical Case Reports, 2018 Background Numerous patients develop diabetes in response to glucocorticoid therapy. This study explored the efficacy, safety, and preventive potential of the dipeptidyl peptidase-4 inhibitor, linagliptin (TRADJENTA®), in the development of ...
Yoshia Miyawaki +12 more
doaj +1 more source